

(b) amino acid residues 2 to 541 of SEQ ID NO:2.

22. (New) The isolated protein of claim 21 which comprises amino acid sequence  
(a).

23. (New) The isolated protein of claim 21 which comprises amino acid sequence  
(b).

24. (New) The protein of claim 21, wherein the amino acid sequence further comprises a heterologous polypeptide.

25. (New) The protein of claim 21, wherein said protein is glycosylated.

26. (New) The protein of claim 21, wherein said protein is fused to polyethyleneglycol.

27. (New) A composition comprising the isolated protein of claim 21 and a pharmaceutically acceptable carrier.

28. (New) A protein produced by a method comprising:  
(a) culturing a host cell under conditions suitable to produce the protein of claim 21; and  
(b) recovering the protein.

29. (New) An isolated protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of the full-length polypeptide, which amino acid sequence is encoded by the cDNA clone contained in ATCC Deposit No. 97186; and

(b) the amino acid sequence of the full-length polypeptide, excluding the amino-terminal methionine residue, which amino acid sequence is encoded by the cDNA clone contained in ATCC Deposit No. 97186.

30. (New) The isolated protein of claim 29 which comprises amino acid sequence  
(a).

31. (New) The isolated protein of claim 29 which comprises amino acid sequence  
(b).

12 32. (New) The protein of claim ~~29~~<sup>9</sup>, wherein the amino acid sequence further comprises a heterologous polypeptide.

13 33. (New) The protein of claim ~~29~~<sup>9</sup>, wherein said protein is glycosylated.

14 34. (New) The protein of claim ~~29~~<sup>9</sup>, wherein said protein is fused to polyethyleneglycol.

15 35. (New) A composition comprising the isolated protein of claim ~~29~~<sup>9</sup> and a pharmaceutically acceptable carrier.

36. (New) A protein produced by a method comprising:  
(a) culturing a host cell under conditions suitable to produce the protein of claim 29; and  
(b) recovering the protein.

37. (New) An isolated protein comprising an amino acid sequence 90% or more identical to amino acid residues 2 to 541 of SEQ ID NO:2.

38. (New) The isolated protein of claim 37 which further comprises an amino acid sequence 95% or more identical to amino acid residues 2 to 541 of SEQ ID NO:2.

39. (New) The protein of claim 37, wherein the amino acid sequence further comprises a heterologous polypeptide.

40. (New) The protein of claim 37, wherein said protein is glycosylated.

41. (New) The protein of claim 37, wherein said protein is fused to polyethyleneglycol.

42. (New) A composition comprising the isolated protein of claim 37 and a pharmaceutically acceptable carrier.

43. (New) A protein produced by a method comprising:  
(a) culturing a host cell under conditions suitable to produce the protein of claim 37; and  
(b) recovering the protein.

*Def C3*

44. (New) An isolated protein comprising an amino acid sequence 90% or more identical to the amino acid sequence of the full-length polypeptide excluding the amino-terminal methionine, which amino acid sequence is encoded by the cDNA contained in ATCC Deposit No. 97186.

45. (New) The isolated protein of claim 44 which further comprises an amino acid sequence 95% or more identical to the amino acid sequence of the full-length polypeptide, excluding the amino-terminal methionine, which amino acid sequence is encoded by the cDNA contained in ATCC Deposit No. 97186.

46. (New) The protein of claim 44, wherein the amino acid sequence further comprises a heterologous polypeptide.

47. (New) The protein of claim 44, wherein said protein is glycosylated.

48. (New) The protein of claim 44, wherein said protein is fused to polyethyleneglycol.

*B3*

49. (New) A composition comprising the isolated protein of claim 44 and a pharmaceutically acceptable carrier.

50. (New) A protein produced by a method comprising:  
(a) culturing a host cell under conditions suitable to produce the protein of claim 44; and  
(b) recovering the protein.

51. (New) An isolated protein comprising an amino acid sequence selected from the group consisting of:

- (a) amino acid residues 24 to 36 of SEQ ID NO:2;
- (b) amino acid residues 56 to 80 of SEQ ID NO:2;
- (c) amino acid residues 92 to 142 of SEQ ID NO:2;
- (d) amino acid residues 214 to 233 of SEQ ID NO:2;
- (e) amino acid residues 310 to 315 of SEQ ID NO:2;
- (f) amino acid residues 349 to 363 of SEQ ID NO:2;
- (g) amino acid residues 415 to 428 of SEQ ID NO:2;
- (h) amino acid residues 435 to 449 of SEQ ID NO:2;
- (i) amino acid residues 457 to 464 of SEQ ID NO:2;
- (j) amino acid residues 476 to 487 of SEQ ID NO:2;

- (k) amino acid residues 496 to 504 of SEQ ID NO:2; and
- (l) amino acid residues 508 to 541 of SEQ ID NO:2.

52. (New) The isolated protein of claim 51, wherein said amino acid sequence is (a).
53. (New) The isolated protein of claim 51, wherein said amino acid sequence is (b).
54. (New) The isolated protein of claim 51, wherein said amino acid sequence is (c).
55. (New) The isolated protein of claim 51, wherein said amino acid sequence is (d).
56. (New) The isolated protein of claim 51, wherein said amino acid sequence is (e).
57. (New) The isolated protein of claim 51, wherein said amino acid sequence is (f).
58. (New) The isolated protein of claim 51, wherein said amino acid sequence is (g).
59. (New) The isolated protein of claim 51, wherein said amino acid sequence is (h).
60. (New) The isolated protein of claim 51, wherein said amino acid sequence is (i).
61. (New) The isolated protein of claim 51, wherein said amino acid sequence is (j).
62. (New) The isolated protein of claim 51, wherein said amino acid sequence is (k).
63. (New) The isolated protein of claim 51, wherein said amino acid sequence is (l).
64. (New) The isolated protein of claim 51, wherein said amino acid sequence is (a), and wherein said amino acid sequence further comprises amino acid sequence (b).
65. (New) The protein of claim 51, wherein the amino acid sequence further comprises a heterologous polypeptide.
66. (New) The protein of claim 51, wherein said protein is glycosylated.
67. (New) The protein of claim 51, wherein said protein is fused to polyethyleneglycol.

68. (New) A composition comprising the isolated protein of claim 51 and a pharmaceutically acceptable carrier.

69. (New) A protein produced by a method comprising:  
(a) culturing a host cell under conditions suitable to produce the protein of claim 51; and  
(b) recovering the protein.

16 70. (New) An isolated protein comprising at least 30 contiguous amino acid residues of SEQ ID NO:2.

17 71. (New) The isolated protein of claim 70 wherein the isolated protein comprises at least 50 contiguous amino acid residues of SEQ ID NO:2.

18 72. (New) The protein of claim 70, wherein the amino acid sequence further comprises a heterologous polypeptide.

19 73. (New) The protein of claim 70, wherein said protein is glycosylated.

20 74. (New) The protein of claim 70, wherein said protein is fused to polyethyleneglycol.

21 75. (New) A composition comprising the protein of claim 70 and a pharmaceutically acceptable carrier.

Dep-C4 76. (New) A protein produced by a method comprising:  
(a) culturing a host cell under conditions suitable to produce the isolated protein of claim 70; and  
(b) recovering the protein.--

#### Remarks

The Specification has been amended to correct obvious typographical errors and to insert appropriate sequence identifiers. The specification has also been amended to incorporate ATCC Deposit No. 97186 deposited on June 1, 1995 under 37 C.F.R. § 1.804 (a) and § 1.806.